We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
-6.2%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.65B
AUM Growth
-$362M
(-18%)
Cap. Flow
-$188M
Cap. Flow
% of AUM
-11.37%
Top 10 Holdings %
Top 10 Hldgs %
71.92%
Holding
40
New
3
Increased
6
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Recursion Pharmaceuticals
RXRX
|
+$68M |
| 2 |
ASML
ASML
|
+$23.3M |
| 3 |
CBLL
CeriBell Inc
CBLL
|
+$8.96M |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$8.79M |
| 5 |
ZBIO
Zenas BioPharma
ZBIO
|
+$7.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Corcept Therapeutics
CORT
|
+$112M |
| 2 |
Cable One
CABO
|
+$41.4M |
| 3 |
Brookfield
BN
|
+$39.1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$32.6M |
| 5 |
Brookfield Asset Management
BAM
|
+$29.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.4% |
| 2 | Technology | 13.01% |
| 3 | Financials | 9.73% |
| 4 | Consumer Discretionary | 2.32% |
| 5 | Industrials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$646B
| $301M | 18.22% |
1,038,550
| – | – |
|
|
2
Brookfield
BN
$102B
| $161M | 9.73% |
4,198,245
-1,038,600
| -20% | -$39.1M |
|
|
TEM
3
Tempus AI
TEM
$7.48B
| $138M | 8.33% |
4,074,419
| – | – |
|
4
Edgewise Therapeutics
EWTX
$4.28B
| $134M | 8.08% |
5,000,000
-549,900
| -10% | -$17.5M |
|
|
5
ASML
ASML
$596B
| $115M | 6.96% |
165,836
+32,500
| +24% | +$23.3M |
|
6
Salesforce
CRM
$154B
| $98.3M | 5.95% |
293,901
-74,659
| -20% | -$23.8M |
|
|
7
Recursion Pharmaceuticals
RXRX
$1.58B
| $68.4M | 4.14% |
+10,114,633
| New | +$68M |
|
8
Mirum Pharmaceuticals
MIRM
$6.56B
| $62M | 3.76% |
1,500,000
| – | – |
|
9
Vaxcyte
PCVX
$7.65B
| $61.4M | 3.72% |
750,000
| – | – |
|
10
Insmed
INSM
$22.4B
| $50M | 3.03% |
724,666
| – | – |
|
11
Crinetics Pharmaceuticals
CRNX
$8.88B
| $49.1M | 2.97% |
960,215
-39,785
| -4% | -$2.23M |
|
12
Viridian Therapeutics
VRDN
$2.2B
| $43.1M | 2.61% |
2,250,000
-135,000
| -6% | -$2.94M |
|
13
ArriVent BioPharma
AVBP
$1.4B
| $40.5M | 2.45% |
1,520,627
+15,312
| +1% | +$440K |
|
14
Alibaba
BABA
$276B
| $38.4M | 2.32% |
452,327
-48,500
| -10% | -$4.58M |
|
15
Pharvaris
PHVS
$2.28B
| $33.1M | 2% |
1,725,000
| – | – |
|
16
BioMarin Pharmaceuticals
BMRN
$11.9B
| $32.2M | 1.95% |
490,000
| – | – |
|
|
MRUS
17
DELISTED
Merus
MRUS
| $31.5M | 1.91% |
750,000
+50,000
| +7% | +$2.4M |
|
18
Celldex Therapeutics
CLDX
$2.94B
| $25.3M | 1.53% |
1,000,000
+36,337
| +4% | +$987K |
|
|
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
| $24M | 1.45% |
1,663,724
+119,724
| +8% | +$2.17M |
|
|
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
| $23.6M | 1.43% |
2,500,000
| – | – |
|
21
LanzaTech
LNZA
$59.9M
| $21.7M | 1.31% |
158,148
| – | – |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $15.3M | 0.92% |
175,000
| – | – |
|
23
Rocket Pharmaceuticals
RCKT
$343M
| $13.8M | 0.84% |
1,100,000
| – | – |
|
|
VERV
24
DELISTED
Verve Therapeutics
VERV
| $13.5M | 0.82% |
2,400,000
| – | – |
|
|
ZBIO
25
Zenas BioPharma
ZBIO
$1.96B
| $13.1M | 0.79% |
1,600,000
+450,000
| +39% | +$7.02M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q4 2024 Portfolio in Review
As of Q4 2024, Novo Holdings A/S held 40 positions worth $1.65B, down 18% from $2.01B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Novo Holdings A/S withdrew a net $188M in Q4 2024, closing 6 positions and reducing 6 holdings. Its most notable exit was Corcept Therapeutics, an estimated $112M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Recursion Pharmaceuticals worth $68.4M.
- Novo Holdings A/S's largest Q4 2024 buy was Recursion Pharmaceuticals: 10,114,633 shares worth $68.4M.
- Novo Holdings A/S added most to ASML in Q4 2024, an estimated $23.3M increase.
- Novo Holdings A/S's biggest Q4 2024 reduction was Brookfield, cutting an estimated $39.1M.
- Novo Holdings A/S fully exited Corcept Therapeutics in Q4 2024, selling an estimated $112M.
- Novo Holdings A/S's ten largest holdings make up 72% of its $1.65B portfolio in Q4 2024.
- Novo Holdings A/S opened 3 new positions and closed 6 in Q4 2024.
- Novo Holdings A/S's portfolio value fell 18% quarter-over-quarter to $1.65B.
Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.